Empagliflozin in non alcoholic fatty liver

Phase 1

• Conditions: Diabetic patient with non alcoholic fatty liver.; Other specified inflammatory liver diseases; K75.8

• Registration Number: IRCT20150706023084N18
• Lead Sponsor: Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Diabetic patient
Fatty liver
Empagliflozin

Exclusion Criteria

Drug use for fatty liver

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Different grades of fatty liver. Timepoint: Before the intervention and 30 days after it, the question paper and sonography and fibroscan analysis data will be evaluated. Method of measurement: Investigating of sonography(fibroscan).

Secondary Outcome Measures

Name	Time	Method
Investigating sonography related to the course of recovery during treatment. Timepoint: From the beginning of treatment for 3 month. Method of measurement: Examining the sonography of the patients.